Searched for
JAPAN DRUG SUPPLY
US stocks: US market ends lower as tech stocks weigh on sentimentWall Street ended lower on Friday, with AI chip stocks experiencing a significant downturn while Moderna and other healthcare companies sur...- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsFrom a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...
- Japanese investors are looking beyond China... India is key alternative: Tsutomu Takemura, Senior MD, NomuraIndia is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...
- Stock picks of the week; 5 stocks with consistent score improvement and upside potential of up to 25%Even in normal times it is futile to try and guess the outcome of most global events. But in the New World Order, it makes no sense at all ...
- India’s rising export champion faces a critical credibility testIndia's seafood exports are soaring, reaching record highs and aiming for $30 billion within five years. Despite overcoming US tariffs and ...
- Banned substance in shrimp: Vet shops under close watchIndia's top drug regulator is cracking down on veterinary shops. This action follows a significant rejection of shrimp exports to major mar...
- 'Seriously concerned': Quad joint statement flags water cannons, blocked ships in South and East China SeasIndia, US, Japan, and Australia foreign ministers met in New Delhi. They voiced serious concerns over the South China and East China Seas. ...
- Hantavirus: Britain secures experimental Japanese drug to strengthen responseBritain has received experimental favipiravir from Japan to treat a deadly hantavirus outbreak. The drug is not licensed in the UK and its ...
- India losing investor attention to Asia’s AI-electronics surge, says DBS economistGlobal capital is shifting towards electronics and AI in Asia. India's foreign direct investment slowdown is not a major concern. Asia's ex...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAs far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- India following diversified strategy to boost exports to China, cut import dependence: OfficialIndia is pursuing a multi-pronged approach to boost its exports to China. The nation is focusing on building its own industrial capabilitie...
- Stock Market Crash Today: D-Street investors lose Rs 5 lakh crore. 7 reasons why Sensex and Nifty fellIndian stock markets experienced sharp losses for the third consecutive session, with Sensex and Nifty falling over 1% each. Escalating Ira...
- India largely shielded from US tariffs on patented drugs due to generic export strength: GTRINew US tariffs on patented drugs will not significantly impact India. The country mainly exports affordable generic medicines to America. T...
- Japan's Nikkei falls on slowdown worries, energy losses"Investors' focus have shifted to slowdown risks stemming from the ongoing tightening monetary policy," said Ikuo Mitsui, fund manager at A...
- Indian drug companies start off a price war on experimental Covid-19 drugOver the next few weeks, close to 10 drug companies including Abbott, Lupin, Micro Labs, Mcleods Pharma, Cipla, Strides Pharma and Dr Reddy...
- Dr Reddy’s partners Fujifilm to launch Avigan for Covid-19 treatmentThe agreement provides for Fujifilm Toyama Chemical, a unit of the Japanese company to grant Dr. Reddy's and Dubai-based Global Response Ai...
- Cipla in talks to supply drugs to Germany’s BIBoehringer Ingelheim in talks with Cipla for supply of generic drugs to the $17-bn German coa for two drugs.
- Ranbaxy exits Nihon JV, sells out to partnerRanbaxy Laboratories on Tuesday said it was selling its 50 per cent stake in its Japanese joint venture Nihon Pharmaceutical Industry (NPI)...
- Ranbaxy to supply raw materials for anti-ulcer drugRanbaxy Laboratories, India's largest company by sales, is expected to start supplying raw materials for anti-ulcer drug esomeprazole magne...
Load More
